● Recruiting

PRasugrEl Monotherapy Following prImary percUtaneous Coronary Intervention for ST-elevation Myocardial Infarction

Condition: ST-segment Elevation Myocardial Infarction (STEMI) · Sponsor: Kindai University

PhasePhase 4

Planned participants2258

Who can joinAll sexes, 18 Years to no upper limit

Healthy volunteersNo

About this study

The aim of this study is to evaluate the safety of prasugrel monotherapy without aspirin versus 12-month dual antiplatelet therapy (DAPT) in patients with STEMI using platinum-chrome everolimus-eluting stent (PtCr-EES: SYNERGYTM).

This description comes directly from the study's public registry record.

Talk to the study team

Kuniaki Takahashi, MD, PhD · +81-72-366-0221 · kuniaki.t.0125@gmail.com

Always discuss trial participation with your own doctor first.

Locations (1)

Kindai University Faculty of Medicine

Sayama, Osaka, Japan

Recruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT05709626